共 50 条
Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound
被引:6
|作者:
Lu, Xiu-Yun
[1
,2
]
Guo, Xi
[3
]
Zhang, Qi
[2
]
Qiu, Yi-Jie
[2
]
Zuo, Dan
[2
]
Chen, Sheng
[2
]
Tian, Xiao-Fan
[2
]
Zhou, Yu-Hong
[3
]
Dong, Yi
[2
,4
]
Wang, Wen-Ping
[2
]
机构:
[1] Shanghai Inst Med Imaging, Shanghai 200032, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Ultrasound, Shanghai 200032, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai 200032, Peoples R China
[4] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Ultrasound, Shanghai 200092, Peoples R China
来源:
基金:
中国国家自然科学基金;
关键词:
dynamic contrast-enhanced ultrasound (DCE-US);
chemoradiotherapy (CRT);
locally advanced pancreatic ductal adenocarcinoma (LAPC);
treatment response;
time-intensity curves (TICs);
quantitative parameters;
DCE-US;
CLINICAL-PRACTICE;
EARLY PREDICTION;
QUANTIFICATION;
GEMCITABINE;
THERAPY;
MASSES;
HIFU;
CEUS;
EUS;
D O I:
10.3390/diagnostics12112662
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, patients with biopsy-proved and histopathologically proved LAPC who underwent regular CRT were recruited. DCE-US evaluations were performed before and four months after CRT. SonoVue-enhanced contrast-enhanced ultrasound (CEUS) was performed by an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, USA) equipped with a 5C1 MHz convex array transducer. Time-intensity curves were created by VueBox software (Bracco, Italy), and various DCE-US quantitative parameters were obtained. Taking Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomography (CT) or magnetic resonance imaging (MRI) as the gold standard, DCE-US parameters were compared between the treatment responder group (RG) and non-responder group (NRG). The correlation between the DCE-US parameters and the serum carbohydrate antigen 19-9 (CA 19-9) level was also analyzed. Results: Finally, 21 LAPC patients (mean age 59.3 +/- 7.2 years) were included. In comparing the RG (n = 18) and NRG (n = 3), no significant change could be found among the mean size of the lesions (31.2 +/- 8.1 mm vs. 27.2 +/- 8.3 mm, p = 0.135). In comparing the TICs between the two groups, the LAPC lesions in the RG took a longer time to reach peak enhancement and to wash out. Among all the DCE-US parameters, RT (rise time), WiAUC (wash-in area under the curve), WoAUC (wash-out area under the curve) and WiWoAUC (wash-in and wash-out area under the curve) decreased significantly after CRT in the RG (p < 0.05). The RT ratio, WiAUC ratio, WoAUC ratio and WiWoAUC ratio were closely correlated with the change in serum CA 19-9 level in the RG (p < 0.05). Conclusion: DCE-US might be a potential imaging method for non-invasive follow-up for early response in LAPC patients treated by CRT.
引用
收藏
页数:12
相关论文